⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
prnewswire.com
ABBV
AMGN
AZN
BMY
GILD
JNJ
LLY
MRK
NVS
PFE
SNY
TMO
Alzheimer's Therapeutics Market to Reach USD 10.4 Billion by 2036 as Disease-Modifying Immunotherapies Transform Treatment Paradigms
accessnewswire.com
ABBV
BMY
JNJ
LLY
NVS
REGN
BIIB
BioNJ Elects Board Officers and Trustees
prnewswire.com
GMAB
MRK
AMTX
JNJ
ASND
ACAD
BMY
PFE
PTC
NVS
SNY
CLDX
ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS
globenewswire.com
ATAI
JNJ
BMY
NVS
Niowave and Novartis Enter Global Actinium-225 Supply Agreement to Advance Next-Generation Cancer Therapies
prnewswire.com
NVS
Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica
globenewswire.com
JNJ
AZN
MRK
ORCL
IQV
PFE
NVS
TAK
BMY
SNY
LLY
GILD
ACN
DLTR
IBM
Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million
globenewswire.com
NVS
SRPT
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
globenewswire.com
NVS
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
globenewswire.com
NVS
Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals
globenewswire.com
NVS
GILD
BMY
REGN
CRSP
NTLA
EDIT
BBIO
AZN
SGMO